Chongqing Boteng Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, without false records, misleading statements, or significant omissions.
Special Reminder:
- The profit distribution plan for the year 2025 is as follows: Based on the total share capital of 542,182,176 shares after deducting the shares repurchased in the buyback account, a cash dividend of 0.90 yuan (tax included) will be distributed for every 10 shares to all shareholders, totaling 48,796,395.84 yuan (tax included). No bonus shares will be issued, and no capital reserve will be converted into share capital; the remaining undistributed profits will be carried forward to the next year.
- After the announcement of this profit distribution plan and before its implementation, if the total share capital of the Company changes due to stock incentive exercises, new shares being listed, share buybacks, etc., the distribution ratio calculated based on the latest total share capital will be disclosed in the profit distribution implementation announcement, adhering to the principle that "the total amount of cash dividends, bonus shares, and capital increase remains fixed."
- The profit distribution plan does not involve any circumstances that may trigger other risk warnings as stipulated in Article 9.4 (8) of the Shenzhen Stock Exchange's Listing Rules for Growth Enterprises.
I. Review Procedure
Chongqing Boteng Pharmaceutical Technology Co., Ltd. held the seventh meeting of the sixth Board of Directors on April 2, 2026, to review and approve the "Profit Distribution Plan for the Year 2025," which will be submitted to the Company's 2025 Annual General Meeting for consideration.